Reduction of PANTETHINE (cas 138148-35-3) in rabbit ocular lens homogenate
-
Add time:08/20/2019 Source:sciencedirect.com
In several animal models, preliminary studies have indicated that PANTETHINE (cas 138148-35-3) may inhibit cataract formation. Therefore, preclinical trials need to be conducted to study the pharmacology of pantethine in the ocular lens and to establish its efficacy. Since pantethine, which is a disulfide, can undergo a variety of chemical modifications such as reduction and formation of mixed disulfides, a detailed study was first conducted to determine the stability of pantethine in rabbit lens homogenate. A knowledge of the stability of pantethine in lens homogenate was necessary to establish if pantethine could be metabolized in the time it takes to harvest and homogenize a lens. The results of this study will be used to establish a protocol for harvesting and homogenizing lens samples.Pantethine (100 μM) is completely reduced to pantetheine in rabbit lens homogenate in about 16 min. About 1.5% of the pantethine added to lens homogenate forms a mixed disulfide with lens proteins, and the remainder is found in the supernatant. The supernatant pantethine concentration decreases exponentially as a function of time, and the terminal half-life for this process is 3.3 min. The free supernatant pantetheine concentration increases in pseudo first order manner as a function of time with a rate constant of 4.3 min. Pantethinase activity is not significant, because the free supernatant pantetheine concentration did not decrease. The exact mechanism of pantethine reduction in rabbit lens homogenate remains to be determined.
We also recommend Trading Suppliers and Manufacturers of PANTETHINE (cas 138148-35-3). Pls Click Website Link as below: cas 138148-35-3 suppliers
Prev:Review articleTreatment of hyperlipoproteinemia with PANTETHINE (cas 138148-35-3): A review and analysis of efficacy and tolerability
Next:Research paperPANTETHINE (cas 138148-35-3) lipomodulation: evidence for cysteamine mediation in vitro and in vivo) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- PANTETHINE (cas 138148-35-3) stimulates lipolysis in adipose tissue and inhibits cholesterol and fatty acid synthesis in liver and intestinal mucosa in the normolipidemic rat08/25/2019
- BBA reportModulation of HMG-CoA reductase activity by pantetheine/PANTETHINE (cas 138148-35-3)08/24/2019
- Research paperEffects of PANTETHINE (cas 138148-35-3) on in-vitro peroxidation of low density lipoproteins☆08/23/2019
- PANTETHINE (cas 138148-35-3), a somatostatin depleting agent, increases food intake in rats☆08/22/2019
- Research paperPANTETHINE (cas 138148-35-3) lipomodulation: evidence for cysteamine mediation in vitro and in vivo08/21/2019
- Review articleTreatment of hyperlipoproteinemia with PANTETHINE (cas 138148-35-3): A review and analysis of efficacy and tolerability08/19/2019
- Original ArticleEfficacy and tolerability of coenzyme A vs PANTETHINE (cas 138148-35-3) for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study08/18/2019
- Original articleComparison of the effects of PANTETHINE (cas 138148-35-3) and fursultiamine on plasma levels of adrenocorticotropic hormone and neuropeptide Y under continual stress exposure08/17/2019


